ArticleWorld journal of clinical cases2025
Clots in colitis: Thromboembolism and beyond.
Article in World journal of clinical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with ulcerative colitis (UC) have an increased risk of thromboembolic events, particularly venous thromboembolism (VTE), which encompasses deep vein thrombosis and pulmonary embolism. The incidence of VTE in patients with UC is significantly higher than that in the general population, and a retrospective cohort study found that patients undergoing colectomy had a notable risk of developing VTE, with rates reaching as high as 22% among patients exposed to tofacitinib within a month prior to surgery. The GETAID FOCUS study also reported a high prevalence of self-reported VTE in patients with UC, with a pooled prevalence of approximately 12% across various studies. The risk of thromboembolism in UC is multifactorial and influenced by chronic inflammation, a wide range of medications used, potential surgical interventions, and possibly genetic factors or associations that are yet to be fully defined. Recognizing the various contributing factors is crucial for developing effective preventive strategies and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.